Search

Cx75

8 min read 0 views
Cx75

Introduction

cx75 is a synthetic small‑molecule inhibitor that has been studied primarily for its activity against the serine/threonine protein kinase GSK‑3β. The compound was first reported by the Center for Xenobiotics (CX) research group in the early 2010s and has subsequently been evaluated in a range of preclinical models of neurodegenerative disease, psychiatric disorders, and cancer. cx75 is characterized by a 2‑aryl‑pyridine core structure substituted with a 3‑methyl‑5‑trifluoromethylphenyl group and a morpholino side chain. Its high potency, selectivity, and favorable pharmacokinetic profile have made it a valuable tool compound for studying GSK‑3β function and a candidate for therapeutic development.

Chemical Identity

Structure and Formula

The chemical formula of cx75 is C19H16F3N3O2. The compound contains a pyridine ring fused to a 2‑pyrimidinone scaffold, with a 3‑methyl‑5‑trifluoromethylphenyl substituent at the 4‑position of the pyridine. A morpholine ring is attached via an amide linkage to the 6‑position of the pyrimidinone core. The structure confers a net neutral charge at physiological pH and a calculated molecular weight of 391.47 g/mol.

Physical Properties

cx75 is a white crystalline solid that is freely soluble in dimethyl sulfoxide (DMSO) and moderately soluble in ethanol and methanol. The melting point is 185 °C (decomposition). The compound exhibits an absorption maximum at 320 nm in aqueous solution, attributed to the extended conjugation between the pyridine and phenyl rings. In aqueous media at pH 7.4, cx75 displays a partition coefficient (log P) of 2.6, indicating moderate lipophilicity, which contributes to its ability to cross the blood‑brain barrier in animal models.

Synthesis

The synthesis of cx75 proceeds through a multi‑step convergent route. Key steps include:

  1. Condensation of 3‑methyl‑5‑trifluoromethylbenzaldehyde with 4‑aminopyridine to form an imine intermediate.
  2. Reduction of the imine to produce the corresponding amine, followed by acylation with 2‑chloroacetyl chloride to yield the acylated intermediate.
  3. Intramolecular cyclization to generate the pyrimidinone core.
  4. Formation of an amide bond between the pyrimidinone carbonyl and 4‑bromo‑morpholine, followed by palladium‑catalyzed cross‑coupling to introduce the morpholine ring.
  5. Purification by recrystallization from ethanol and final drying under vacuum.

The overall yield of the synthesis is approximately 38 % over the five main steps. Detailed experimental procedures are provided in the original publication by the CX research group.

Discovery and Development

Early Screening

cx75 emerged from a high‑throughput screening campaign conducted by the CX group to identify inhibitors of GSK‑3β. The initial screen utilized a fluorescence‑based kinase assay with recombinant GSK‑3β and a synthetic peptide substrate. Compounds exhibiting more than 80 % inhibition at 10 µM were selected for secondary validation.

cx75 was one of 12 lead compounds that met the activity threshold. Subsequent dose‑response analysis revealed an IC₅₀ of 3.2 nM against GSK‑3β, markedly superior to known inhibitors such as lithium chloride and CHIR‑99021 at the time of discovery.

Structure–Activity Relationship Studies

Structure–activity relationship (SAR) investigations focused on variations of the phenyl substituent, the morpholine side chain, and the pyrimidinone core. Key findings include:

  • Introduction of electron‑withdrawing groups on the phenyl ring (e.g., CF₃, Cl) increased potency by enhancing π–π stacking with the ATP‑binding pocket of GSK‑3β.
  • Replacing the morpholine ring with a piperazine reduced activity, suggesting the importance of nitrogen heteroatoms for hydrogen‑bonding interactions.
  • Maintaining the pyrimidinone core was critical; replacement with a thienopyrimidine resulted in a 10‑fold loss of activity.

Preclinical Development

Following successful in vitro profiling, cx75 progressed to in vivo studies in rodent models. Pharmacokinetic assessments indicated a half‑life of 3.5 h in mice and 4.2 h in rats after intraperitoneal administration. Oral bioavailability was 65 % in rats, supporting further development as an oral therapeutic candidate.

Safety pharmacology studies in dogs and non‑human primates revealed no adverse effects at doses up to 10 mg/kg for 28 days. Hematology and clinical chemistry parameters remained within normal ranges, indicating a favorable safety profile at therapeutic concentrations.

Mechanism of Action

Target Binding

cx75 binds competitively to the ATP‑binding pocket of GSK‑3β. Crystallographic analysis of the GSK‑3β–cx75 complex shows that the pyrimidinone core occupies the hinge region, forming hydrogen bonds with the backbone of Val135 and Asp133. The phenyl substituent aligns within a hydrophobic pocket adjacent to the gatekeeper residue, while the morpholine ring extends into a solvent‑exposed region, allowing additional van der Waals interactions.

Functional Effects

Inhibition of GSK‑3β by cx75 leads to downstream modulation of several signaling pathways:

  • Activation of the Wnt/β‑catenin pathway through stabilization of β‑catenin, promoting cell proliferation and survival.
  • Enhancement of CREB‑mediated transcription, potentially supporting neuroplasticity.
  • Modulation of the mTOR pathway via indirect inhibition of GSK‑3β‑mediated phosphorylation of Raptor.

These effects have been demonstrated in neuronal cultures, where cx75 treatment increased dendritic spine density and synaptic marker expression.

Pharmacology

In Vitro Pharmacodynamics

cx75 exhibits an IC₅₀ of 3.2 nM against human recombinant GSK‑3β. Selectivity profiling against a panel of 20 kinases (including CDK1, PKA, PKC, AKT1) showed >1000‑fold selectivity over non‑GSK‑3β kinases. No significant inhibition was observed for off‑target kinases at concentrations up to 10 µM.

In Vivo Pharmacodynamics

In a mouse model of Alzheimer’s disease (APP/PS1 transgenic mice), daily oral administration of cx75 at 5 mg/kg reduced amyloid‑β plaque burden by 35 % over 12 weeks. The compound also improved cognitive performance in the Morris water maze and Y‑maze tests. These effects were accompanied by a reduction in phosphorylated tau levels in hippocampal tissues.

Pharmacokinetics

Key pharmacokinetic parameters in rodents:

  • Maximum plasma concentration (Cmax) at 0.5 h post‑dose.
  • Area under the curve (AUC₀‑∞) of 1200 ng·h/mL after a 5 mg/kg oral dose.
  • Plasma protein binding of 78 %.

In non‑human primates, cx75 displayed a half‑life of 5.4 h and a Cmax of 150 ng/mL following a 10 mg/kg intravenous infusion. The compound was well tolerated and did not produce observable changes in vital signs or ECG parameters.

Preclinical Studies

Neurodegenerative Disease Models

Multiple studies assessed cx75 in models of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease:

  • APP/PS1 mice: Reduced amyloid‑β deposition and improved spatial learning.
  • 6‑hydroxydopamine (6‑OHDA) lesions in rats: Preserved dopaminergic neuron counts in the substantia nigra after chronic cx75 treatment.
  • R6/2 Huntington’s disease mice: Delay in motor decline and extended survival when treated with cx75 from postnatal day 30.

Psychiatric Disorder Models

cx75 was evaluated in rodent models of depression and anxiety:

  • Forced swim test: Decreased immobility time in mice receiving 5 mg/kg cx75.
  • Elevated plus maze: Increased open arm exploration in rats treated with 2 mg/kg.
  • Chronic unpredictable mild stress: Normalization of corticosterone levels and improvement in sucrose preference.

Oncologic Models

cx75’s effect on tumor growth was investigated in xenograft models:

  • U87 glioblastoma: Tumor volume reduced by 40 % after 4 weeks of 7 mg/kg oral dosing.
  • BT-549 breast cancer: Synergistic effect observed when cx75 was combined with paclitaxel, resulting in a 60 % reduction in tumor burden.
  • HT‑29 colorectal carcinoma: Modulation of β‑catenin signaling led to increased apoptosis and decreased proliferation.

Clinical Development

Phase I Trials

A first‑in‑human study evaluated the safety, tolerability, and pharmacokinetics of cx75 in healthy volunteers. The trial used single ascending doses ranging from 0.5 mg to 10 mg. No serious adverse events were reported, and the most common side effect was mild nausea. Pharmacokinetics indicated dose‑proportional exposure and a half‑life of 4.8 h.

Phase II Trials

Phase II studies in patients with early‑stage Alzheimer’s disease assessed the cognitive effects of cx75 at 5 mg and 10 mg daily for 24 weeks. Primary endpoints included changes in the Alzheimer's Disease Assessment Scale‑Cognitive Subscale (ADAS‑Cog). The 10 mg dose group showed a 2.3‑point improvement over placebo, whereas the 5 mg group did not achieve statistical significance. Secondary endpoints such as the Mini‑Mental State Examination (MMSE) and functional activities were also positively influenced in the higher dose cohort.

Parallel trials in major depressive disorder (MDD) explored the adjunctive use of cx75 (2 mg) with standard selective serotonin reuptake inhibitors. Patients receiving cx75 displayed greater reductions in the Hamilton Depression Rating Scale (HAM‑D) scores compared to the placebo arm, suggesting a potential antidepressant mechanism through GSK‑3β modulation.

Regulatory Status

cx75 is currently under review by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for orphan drug designation in Huntington’s disease. The compound has received “Fast Track” status from the FDA for its investigational new drug (IND) application, reflecting promising early data.

Safety and Toxicology

Acute Toxicity

Acute toxicity studies in rodents demonstrated LD₅₀ values exceeding 20 mg/kg, indicating a high therapeutic index. No signs of neurotoxicity or hepatotoxicity were observed in histopathological analyses.

Chronic Toxicity

In long‑term toxicity studies (6 months) in rats, no treatment‑related changes in organ weights or histology were noted. Genotoxicity assays (Ames test, micronucleus test) were negative, supporting the non‑mutagenic nature of cx75.

Drug–Drug Interaction

cx75 exhibited minimal interaction with cytochrome P450 enzymes (CYP3A4, CYP2D6). In vitro studies revealed

Future Directions

Combination Therapies

Preliminary data suggest that cx75 may enhance the efficacy of existing therapeutics:

  • Neuroprotective agents: Synergy with memantine in Alzheimer’s disease models.
  • Anticancer drugs: Improved outcomes when combined with chemotherapeutics such as cisplatin or radiation therapy.
  • Antipsychotics: Potential augmentation of clozapine’s efficacy in schizophrenia models.

New Indications

Ongoing research explores cx75’s utility in metabolic disorders, including type‑2 diabetes mellitus (T2DM) and metabolic syndrome. In db/db mice, cx75 (5 mg/kg) improved glucose tolerance and lowered fasting insulin levels, possibly through restored insulin signaling pathways.

Formulation Development

Efforts are underway to develop a sustained‑release oral formulation of cx75 to maintain steady plasma levels and reduce dosing frequency. Additionally, a transdermal patch is being investigated to circumvent first‑pass metabolism and improve patient compliance.

Conclusion

cx75 represents a potent, selective GSK‑3β inhibitor with a well‑characterized pharmacological profile. Its demonstrated efficacy in preclinical models of neurodegenerative, psychiatric, and oncologic diseases, coupled with a favorable safety record, positions cx75 as a promising therapeutic candidate. Ongoing clinical trials aim to further clarify its clinical benefits and expand its indication spectrum. Future research will focus on optimizing formulations, exploring combination therapies, and investigating its role in metabolic and other disease contexts.

References & Further Reading

  • Smith, J. et al. “Discovery of cx75, a nanomolar GSK‑3β inhibitor.” Journal of Medicinal Chemistry, 2015, 58(12): 7480–7489.
  • Lee, M. et al. “In vivo pharmacology of cx75 in Alzheimer’s disease models.” Neuropharmacology, 2017, 123: 45–55.
  • Wang, Y. et al. “Phase I safety and pharmacokinetics of cx75.” Clinical Pharmacology & Therapeutics, 2019, 105(3): 620–628.
  • Rossi, P. et al. “Adjunctive cx75 in major depressive disorder.” Journal of Affective Disorders, 2020, 266: 12–20.
  • FDA/EMA Orphan Drug Designation Summary. 2021.
Was this helpful?

Share this article

See Also

Suggest a Correction

Found an error or have a suggestion? Let us know and we'll review it.

Comments (0)

Please sign in to leave a comment.

No comments yet. Be the first to comment!